Indaptus Therapeutics Inc (INDP) Stock Price, Quote & News

Company Profile

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The company was formerly kno...

Industry: Biotechnology

Sector: Healthcare

Phone: 646 427 2727

Website: indaptusrx.com

Address:

Three Columbus Circle, 15th Floor, New York, United States

Biomechanika Oct. 7 at 6:20 AM

$INDP This could act like $SPRB on decent news.

1 · Reply

AutoAZTrader Oct. 6 at 7:56 PM

$INDP Can't get off the fucking ground.

0 · Reply

AutoAZTrader Oct. 6 at 7:10 PM

$INDP This fucker can not go up without immediately coming down. Piece of shit.

0 · Reply

Biotoneten Oct. 6 at 6:28 PM

$INDP Holding. No borrow of my shares and limit sell still at $38.

0 · Reply

Thespartantrade Oct. 6 at 4:58 PM

$AIMD $TRNR $INDP $GNLN Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve!

0 · Reply

jmmoore4 Oct. 6 at 4:49 PM

$INDP We need to turn this bad boy around! ⬆️

0 · Reply

lucinith Oct. 6 at 3:49 PM

$INDP no buys. Shirts selling 100 shares at a time to fill the demand. Then buy them back. Short again . Rinse and repeat.

0 · Reply

lucinith Oct. 6 at 3:17 PM

$INDP being shorted .. smh..

1 · Reply

Maazo Oct. 6 at 2:25 PM

$INDP Funny. The number of shares to borrow is growing rapidly, but the borrowing-% is not o)

0 · Reply

RetireB4FortyX Oct. 6 at 12:26 AM

Watchlist for this week: $INDP $SGBX $MAMK

0 · Reply

Indaptus Therapeutics Provides Clinical Update

Sep 2, 2025, 4:05 PM EDT - 4 weeks ago

Indaptus Therapeutics to Present at the H.C. Wainwright 27ᵗʰ Annual Global Investment Conference

Aug 13, 2025, 8:00 AM EDT - 7 weeks ago

Indaptus Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jul 1, 2025, 8:14 AM EDT - 3 months ago

Indaptus Therapeutics, Inc. Announces Additional Sale of $3.4 Million in Private Placement of Convertible Notes and Warrants

Jun 25, 2025, 7:00 AM EDT - 3 months ago

Indaptus Therapeutics Announces Reverse Stock Split

Jun 13, 2025, 8:00 AM EDT - 4 months ago

Indaptus Therapeutics, Inc. Announces Sale of $2.3 Million in Private Placement of Convertible Notes and Warrants

Jun 2, 2025, 8:00 AM EDT - 4 months ago

Indaptus Therapeutics Doses First Patient in Phase 1b/2 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab

May 14, 2025, 8:00 AM EDT - 5 months ago

Indaptus Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 8, 2025, 8:00 AM EDT - 5 months ago

Indaptus Therapeutics Founder and Chief Scientific Officer Dr. Michael Newman Named Chair and Expert Speaker at 6th Annual Cytokine-Based Drug Development Summit

Mar 25, 2025, 8:00 AM EDT - 6 months ago

Indaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 Summit

Mar 20, 2025, 8:00 AM EDT - 7 months ago

Indaptus Therapeutics Reports New Data Demonstrating Successful Broad Immune System Activation in Weekly Dosing Trial of Decoy20

Mar 18, 2025, 8:00 AM EDT - 7 months ago

Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab

Mar 13, 2025, 7:30 AM EDT - 7 months ago

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update

Mar 12, 2025, 4:15 PM EDT - 7 months ago

Registration Is Now Open For Tribe Public's Webinar Event “Keys To The Kingdom: Unlocking The Power Of Your Immune System” Featuring Indaptus Therapeutics' CEO On Monday, March 17, 2025

Mar 4, 2025, 8:00 AM EST - 7 months ago

Indaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening its Intellectual Property for Infectious Disease and Cancer Treatments

Feb 25, 2025, 8:00 AM EST - 7 months ago

Indaptus Therapeutics' Chief Scientific Officer Dr. Michael Newman to Present at the 10th Annual Innate Killer Summit

Feb 5, 2025, 8:00 AM EST - 8 months ago

Indaptus Therapeutics Receives Approval from Health Canada to Expand Clinical Trial of Decoy20

Jan 8, 2025, 8:00 AM EST - 9 months ago

Indaptus Therapeutics Provides Year-End Review and Outlook for 2025

Nov 22, 2024, 8:36 AM EST - 11 months ago

Indaptus Therapeutics, Inc. Announces $2.135 Million Registered Direct Offering and Concurrent Private Placement

Nov 11, 2024, 8:00 AM EST - 11 months ago

Indaptus Therapeutics' Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in Immunology

Nov 7, 2024, 8:00 AM EST - 11 months ago

Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting

Oct 23, 2024, 8:00 AM EDT - 1 year ago

Indaptus Therapeutics to Present at Two Upcoming Investor Conferences

May 8, 2024, 8:00 AM EDT - 1 year ago

Indaptus Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Apr 11, 2024, 7:30 AM EDT - 1 year ago

Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting

Mar 25, 2024, 8:30 AM EDT - 1 year ago

Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual Meeting

Mar 13, 2024, 7:30 AM EDT - 1 year ago

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

Mar 4, 2024, 7:30 AM EST - 1 year ago

Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort

Feb 8, 2024, 8:00 AM EST - 1 year ago

Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels

Jan 4, 2024, 8:00 AM EST - 1 year ago

European Patent Office Approves Key Patent for Indaptus Therapeutics' Platform Technology

Nov 6, 2023, 4:01 PM EST - 2 years ago

Indaptus Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Oct 31, 2023, 9:01 AM EDT - 2 years ago

Indaptus Therapeutics to Present Positive Pharmacodynamic (PD) Immune and Pharmacokinetic (PK) Results with Patients from First Cohort of Ongoing Phase 1 Study of Decoy20 at Cancer Immunotherapy Meeting

Sep 26, 2023, 8:00 AM EDT - 2 years ago

Registration Is Now Open For Tribe Public's Webinar Event "Immunotherapy Reimagined" Featuring Indaptus Therapeutics' CEO On Friday, September 29, 2023

Sep 6, 2023, 8:05 AM EDT - 2 years ago

Indaptus Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 14, 2023, 8:00 AM EDT - 2 years ago

Indaptus Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 10, 2023, 8:45 AM EDT - 2 years ago

Indaptus Therapeutics Announces Opening of Next Cohort in Single Dose Ranging Study of Decoy20

Aug 7, 2023, 8:00 AM EDT - 2 years ago

Indaptus Therapeutics Appoints Industry Veteran Roger Waltzman, M.D. Chief Medical Officer

May 11, 2023, 7:00 AM EDT - 2 years ago

Indaptus Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 9, 2023, 8:00 AM EDT - 2 years ago

Following Granting of Indian Patent, Indaptus Therapeutics Achieves Patent Protection in 32 Countries for Decoy Immunotherapy Platform

May 1, 2023, 8:00 AM EDT - 2 years ago

Indaptus Therapeutics' Chief Scientific Officer Michael Newman, Ph.D. Named a Chair of the 4th STING & TLR-Targeting Therapies Summit

Apr 20, 2023, 4:05 PM EDT - 2 years ago

Indaptus Therapeutics to Present at the Planet MicroCap Showcase: VEGAS 2023

Apr 19, 2023, 9:28 AM EDT - 2 years ago

UPDATE -- Indaptus Therapeutics Presents Data Demonstrating Preclinical Efficacy of Decoy, its Bacteria-Based Immunotherapy Platform Technology, at the American Association for Cancer Research Conference 2023

Apr 19, 2023, 8:05 AM EDT - 2 years ago

Indaptus Therapeutics Presents Data Demonstrating Preclinical Efficacy of Decoy, its Bacteria-Based Immunotherapy Platform Technology, at the American Association for Cancer Research Conference 2023

Mar 22, 2023, 8:00 AM EDT - 2 years ago

Indaptus Therapeutics to Present at the Investor Summit Conference

Mar 17, 2023, 8:00 AM EDT - 2 years ago

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update

Mar 15, 2023, 8:05 AM EDT - 2 years ago

Indaptus Therapeutics to Present Poster on Its Decoy Anti-Tumor Platform at the American Association for Cancer Research Conference 2023

Mar 13, 2023, 8:05 AM EDT - 2 years ago

Indaptus Therapeutics Activates Emory Winship Cancer Institute as Trial Site in INDP-D101, Its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

Mar 7, 2023, 8:05 AM EST - 2 years ago

Indaptus Therapeutics Doses First Subject in its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

Feb 14, 2023, 8:00 AM EST - 2 years ago

Indaptus Therapeutics Names Robert Martell, M.D., Ph.D. to its Board of Directors

Feb 7, 2023, 8:05 AM EST - 2 years ago

Indaptus Therapeutics Activates Morristown Medical Center as Trial Site in INDP-D101, Its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

Dec 13, 2022, 7:30 AM EST - 3 years ago

Indaptus Therapeutics Announces Initiation of First-In-Human, Open Label, Dose Escalation and Expansion Multicenter Phase 1 Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

Biomechanika Oct. 7 at 6:20 AM

$INDP This could act like $SPRB on decent news.

1 · Reply

AutoAZTrader Oct. 6 at 7:56 PM

$INDP Can't get off the fucking ground.

0 · Reply

AutoAZTrader Oct. 6 at 7:10 PM

$INDP This fucker can not go up without immediately coming down. Piece of shit.

0 · Reply

Biotoneten Oct. 6 at 6:28 PM

$INDP Holding. No borrow of my shares and limit sell still at $38.

0 · Reply

Thespartantrade Oct. 6 at 4:58 PM

0 · Reply

jmmoore4 Oct. 6 at 4:49 PM

$INDP We need to turn this bad boy around! ⬆️

0 · Reply

lucinith Oct. 6 at 3:49 PM

$INDP no buys. Shirts selling 100 shares at a time to fill the demand. Then buy them back. Short again . Rinse and repeat.

0 · Reply

lucinith Oct. 6 at 3:17 PM

$INDP being shorted .. smh..

1 · Reply

Maazo Oct. 6 at 2:25 PM

$INDP Funny. The number of shares to borrow is growing rapidly, but the borrowing-% is not o)

0 · Reply

RetireB4FortyX Oct. 6 at 12:26 AM

Watchlist for this week: $INDP $SGBX $MAMK

0 · Reply

hedgezilla_ Oct. 5 at 7:47 AM

$INDP Biotech with phase II catalyst. Trading near cash value. Pure binary event risk. No technical pattern.

1 · Reply

jmmoore4 Oct. 4 at 4:56 PM

$INDP Sucky day yesterday, but the chart looks to be setting up nicely! ⬆️

1 · Reply

TraderJay85 Oct. 3 at 8:17 PM

$INDP small loss 12 cents. 👎 $GORV went to 2.97. 🔥 $GIPR went to 1.78 🔥 $LVWR small loss 12 cent 👎 $CNF broke even 🤷‍♂️ NO EMAILS NO DISCORDS JUST FREE IDEAS TO EVERYONE. HIT THE FOLLOW AND LETS MAKE MONEY TOGETHER.

1 · Reply

Vikingsstrade Oct. 3 at 7:25 PM

0 · Reply

Pacman007 Oct. 3 at 5:31 PM

$INDP so if I am correct they have to pay an approximate fee of 800$ a day to lend 10000 shares ?also weekend days ?!

1 · Reply

Biotoneten Oct. 3 at 4:55 PM

$INDP Enjoy your day shorts. Your end hear is nearing.

0 · Reply

Biotoneten Oct. 3 at 4:54 PM

$INDP Let the ahorts enjoy the day trying to scour for more shares to short or to cover. Turning off borrow feature makes fewer share available to short and setting high limit sells makes nonshares available for them to cover unless they move the proce up bigg.

0 · Reply

Biotoneten Oct. 3 at 4:51 PM

$INDP Naked shorting gonna be the death of shorts here.

0 · Reply

Biotoneten Oct. 3 at 4:50 PM

$INDP This does not even show real resistance until 7.44. And then after that it is wide open.

0 · Reply

Biotoneten Oct. 3 at 4:42 PM

$INDP NUKK was shorted like crazy and the shorts ran out of options finally after several false starts to cover. Since they started covering they haven't stopped. That is what will happen here. NUKK had low volume dumps that never broke theough 5.30 to go lower. They have over 7 mil os.

0 · Reply

Biotoneten Oct. 3 at 4:40 PM

$INDP This will behave just like NUKK. I evem shorted that one. Never broke below 5.30. Now 9+ with 8x the float and OS. This one could catipult to $30 very easily with volume.

0 · Reply

Biotoneten Oct. 3 at 4:21 PM

$INDP Volume is intentionally anemic and taming down price on 100 share and 500 share sells and shorting. Borrowing tuned off. They will not get my shares to ahort. Limit order firmly in place at $38

0 · Reply

Market Cap	3.62M
Revenue (ttm)	0.00
Net Income (ttm)	-15.02M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	108,600
Avg Vol	486,648
Day's Range	N/A - N/A
Shares Out	1.11M
Stochastic %K	7%
Beta	1.13
Analysts	Strong Sell
Price Target	$25.00